an9025
Generic: RAS Inhibitor AN9025
an9025: 1 clinical trial tracked.
an9025 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about an9025, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AN9025 in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Primary endpoint: • Nature and frequency of dose limiting toxicities (DLTs)
Interventionalopen118 targetStarted 2026-01Completion 2028-063 sites · United StatesAdlai Nortye Biopharma Co., Ltd.